The US Kidney Cancer Therapeutics and Diagnostics Market is poised for a steered growth due to rise in cases of kidney cancer, an increase in success rate of targeted therapies, expansion of hospitals and NCI- funded cancer centers, and constant growth in population.
- Rising cases of Kidney Cancer due to today’s drastic lifestyle changes, environmental exposures to certain harmful chemicals, obesity, and poor diet is propelling the growth of US Kidney Cancer Therapeutics and Diagnostics Market.
- Targeted therapy is emerging as a key therapy to treat kidney Cancer and related diseases. As it directly targets molecular and genetic abnormalities and provides increased success rate and patient satisfaction.
- Expansion of Hospitals and NCI-funded cancer centers are helping patients to get advanced treatment at affordable rates which is also fueling the growth in the market.
- Increasing pool of patients is witnessed due to constant growth in the population of US. The rise in patient pool increases the demand for treatment and diagnostics services, resulting in increased demand for innovative technology and treatment advancement, thus fueling the market’s growth.
US Kidney Cancer Therapeutics and Diagnostics Market is expected to grow at a CAGR of 5% in the forecast period (2022-2028) and is being driven due to rise in cases of kidney cancer, an increase in success rate of targeted therapies, expansion of hospitals and NCI- funded cancer centers, and constant growth in population. This article will provide information about the growth drivers of the US Kidney Cancer Therapeutics and Diagnostics market in detail.
1. Rising incidence of Kidney Cancer cases is giving US Kidney Cancer Therapeutics and Diagnostics Market a promising growth
Click here to read full article: US Kidney Cancer Diagnostics Technology
The increasing cases of Kidney Cancer in US is seen as a significant factor in propelling the growth of the Kidney Cancer Therapeutics and Diagnostics Market. The visible rise in Kidney Cancer cases is increasing the demand for advanced solutions. This results in a symbiotic relationship between diversification of patient pool and market’s development.
In 2022, out of around a total of 1,918,03 cancer cases of all types approx. 79,000 cases were of kidney cancer (50.290 male 28,710 female), deaths from kidney cancer were around 14,000. According to The American Cancer Society’s recent estimates, in 2023 81,800 adults (52,360 men and 29,440 women) in the United States will be diagnosed with kidney cancer. The total number of deaths is estimated at 14,890 (9,920 men and 4,970 women).
In US, kidney cancer is considered the sixth most common cancer in men and the ninth most common cancer in women. The average age at which people are diagnosed with kidney cancer is 64, most of the people diagnosed with kidney cancer are of age between 65 to 74. The average 5-year survival rate for kidney cancer in US is around 77%.
Today’s drastic lifestyle changes, environmental exposures to certain harmful chemicals, obesity, and poor diet seem to be the most common reasons for the gradual growth of kidney cancer in today’s world. These lifestyle changes if ignored for a long time, are taking a toll on our health thus increasing the risk and cases of diseases like kidney cancers which propels the growth of Kidney Cancer Therapeutics and Diagnostics Market.
2. Is the success rate of targeted therapy overcoming the demand for other therapies for Kidney Cancer treatment in US?
Targeted therapies are becoming a pivotal growth driver of the US Kidney Cancer and Therapeutics Market, due to their effectiveness and increased patient satisfaction rate. The targeted therapy specifically targets the underlying molecular and genetic abnormalities that fuel the growth of kidney cancer. By altering the side effects by traditional chemotherapy and delivering improved treatment outcomes.
The Cohot study shows that targeted therapy for Kidney cancer or Renal Cell Carcinoma (RCC) has shown increased tolerability and survival rates as compared to non-targeted therapy treatment. Seeing these positive results from targeted therapy, the Food and Drug Administration has approved 12 targeted therapies for the treatment of Kidney cancer since 2005.
The continuous growth of targeted therapies’ precision and effectiveness have not only enhanced patient satisfaction but also fostered substantial growth in the US Kidney Cancer and Therapeutics Market. As the research continuous leading to the innovation of new therapies and markets expansion.
3. Expansion of hospitals and NCI-funded cancer centers helping the patients with better treatment opportunities
Visit this Link: – Request for custom report
The growth of the Kidney Cancer Therapeutics and Diagnostics Market is closely related to the expansion of hospitals and medical centers. They play a critical role in the treatment, diagnosis, and supportive care of the diagnosed patient.
There are around 900 hospitals for treating cancer in US. The best cancer hospitals according to US News and World Report in its annual ranking of American Hospitals are, The University of Texas MD Anderson Cancer Center, The Memorial Sloan Kettering Cancer Center, and Mayo Clinic. The US News and World Report ranks hospitals according to the criteria such as 30-day mortality, 30-day readmission, and how long patients tend to stay in hospital.
There are around 72 National Cancer Institute (NCI) designated Cancer Centers, located in around 36 states and the District of Columbia, that have met the standard of care according to NC. Out of these 72 institutions, 11 are Cancer Centers, 54 are comprehensive cancer centers, and 7 are basic laboratory cancer centers. These cancer centers are funded by NCI to deliver cutting-edge technology and advanced treatment care to patients.
Each year approximately 2,50,000 patients receive their cancer diagnosis at NCI-funded cancer centers and thousands of patients are enrolled in clinical trials for cancer at NCI. These NCI centers also provide public education and outreach campaigns on cancer prevention screening and early diagnosis. These NCI centers have worked hard for decades and have increased the number of cancer survivors in Us and have improved patient’s life immeasurably.
The growth of hospitals and cancer centers in US supports Kidney Cancer Therapeutics and Diagnostics Market by improving access to advanced technology diagnostics, and patient care ultimately driving market growth.
4. Constant population growth in US, leading to large patient pool and an increase in need for advanced treatment and diagnostics technologies
An increase in population has continuously contributed to the growth of the Kidney Cancer Therapeutics and Diagnostics Market. As there is a larger pool of potential patients which leads to increased demand for Kidney Cancer and Diagnostics services and treatment options. With a large patient base, pharmaceutical companies and medical product manufacturers are encouraged to invest more in research and development of diagnostic tools and innovative therapies.
According to the data the population of US as of 2022, was approx. 336 million; and around 330 million in 2021. The population growth rate of US in 2022 was around 0.38% as compared to the growth rate in 2021 at around 0.30%. As of 2023, the growth rate is 0.50%.
A larger population allows a broader recruitment pool for clinical trials too, enabling the validation of new treatment modes. Overall, the expanding population is not only driving the growth of US Kidney Cancer Therapeutics and Diagnostics Market but also fuels innovation in the market at a continuous level.
The escalating cases of kidney cancer in the US have created a dynamic synergy that drives the growth of the Kidney Cancer Therapeutics and Diagnostics Market. The visible rise in cases intensifies the demand for advanced solutions, spurring investment in research and development. Targeted therapies emerge as a game-changer, offering precision and effectiveness, while the expansion of hospitals amplifies patient access to cutting-edge diagnostics and treatments. With a steadily increasing population contributing to a larger patient base, pharmaceutical advancements, and research collaboration thrive. As the market evolves to meet these challenges, it stands poised for continuous development, bolstered by innovations that improve patient outcomes and redefine the landscape of kidney cancer care.